Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 8/20 | 0.50 |
| ▸ | MAOA | P21397 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 4/20 | 0.47 |
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA9 | Q16790 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19646242 | 0.85 | CA12 (0.42) | MAPTMEN1KMT2AMAOBMAOA | |
| SCHEMBL29853608 | 0.82 | PREP (0.42) | MAPTMEN1KMT2ACA12CA1 | |
| SCHEMBL26781090 | 0.82 | PREP (0.42) | MAPTMEN1KMT2ACA12CA1 | |
| SCHEMBL3139725 | 0.81 | MAOB (0.53) | MAPTMEN1KMT2AMAOBMAOA | |
| SCHEMBL1324057 | 0.79 | MAOB (0.50) | MAPTMEN1KMT2AMAOBMAOA | |
| SCHEMBL19197256 | 0.79 | PREP (0.39) | MAPTMEN1KMT2AMAOBHSD17B10 | |
| SCHEMBL16847177 | 0.78 | MAPT (0.38) | MAPTMEN1KMT2AMAOBHSD17B10 | |
| SCHEMBL68899 | 0.78 | MAPT (0.59) | MAPTMEN1KMT2AMAOBMAOA | |
| SCHEMBL31689707 | 0.78 | MAPT (0.59) | MAPTMEN1KMT2AMAOBMAOA | |
| SCHEMBL10042955 | 0.76 | CYP19A1 (0.58) | CA12CA1CA9PREPCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331711-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | BAUSCH + LOMB IRELAND LIMITED (IE) | 2023-10-19 | — | — | US | disclosed |
| US-20230331711-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | BAUSCH + LOMB IRELAND LIMITED (IE) | 2023-10-19 | — | — | US | disclosed |
| US-20220073500-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2022-03-10 | — | — | US | disclosed |
| US-11028077-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2021-06-08 | — | — | US | disclosed |
| US-10906892-B2 | LFA-1 inhibitor and methods of preparation and polymorph thereof | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2021-02-02 | — | — | US | disclosed |
| WO-2019076343-A1 | PD-1/PD-L1 SMALL-MOLECULE INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海长森药业有限公司 | 2019-04-25 | — | — | WO | disclosed |
| US-20180118726-A1 | LFA-1 INHIBITOR AND METHODS OF PREPARATION AND POLYMORPH THEREOF | SARCODE BIOSCIENCE INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118726-A1 | LFA-1 INHIBITOR AND METHODS OF PREPARATION AND POLYMORPH THEREOF | SARCODE BIOSCIENCE INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-9890141-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890141-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2018-02-13 | — | — | US | disclosed |
| WO-2008141119-A2 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-20 | — | — | WO | disclosed |
| US-7442808-B2 | e.g. 3-(indan-1-yloxy)-8-(oxazolidin-2,4-dion-5-yl)-5,6,7,8-tetrahydroquinoline; with other active ingredients; agonists of G-protein coupled receptor 40 (GPR40); antidiabetic, hypoglycemic agent; non-insulin dependent diabetes, obesity, hyperlipemia | MERCK & CO., INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442808-B2 | e.g. 3-(indan-1-yloxy)-8-(oxazolidin-2,4-dion-5-yl)-5,6,7,8-tetrahydroquinoline; with other active ingredients; agonists of G-protein coupled receptor 40 (GPR40); antidiabetic, hypoglycemic agent; non-insulin dependent diabetes, obesity, hyperlipemia | MERCK & CO., INC. (US) | 2008-10-28 | — | — | US | disclosed |
| WO-2007136572-A2 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007136573-A2 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070265332-A1 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
| US-20070265332-A1 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
| US-6689798-B2 | STEROID ALPHA-HYDROXYLASE AND STEROID LYASE INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-02-10 | — | — | US | disclosed |
| US-20030149079-A1 | Novel benzofuran derivatives | DAIICHI PHARMACEUTICAL CO., LTD. | 2003-08-07 | — | — | US | disclosed |
| EP-1283208-A1 | NOVEL BENZOFURAN DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149079-A1 | Novel benzofuran derivatives | CYP17A1, CYP21A2, HSD17B7 | MAPT 2881/4885MEN1 2683/4885KMT2A 1790/4885 |
| US-20070265332-A1 | Antidiabetic bicyclic compounds | GPR119, GPR65, FFAR4 | MAPT 3890/4885MEN1 4694/4885KMT2A 2468/4885 |
| US-11028077-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | VCAM1, ICAM1, HLA-DRB1 | MAPT 2847/4885MEN1 2506/4885KMT2A 4336/4885 |
| US-20220073500-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | VCAM1, ICAM1, HLA-DRB1 | MAPT 2847/4885MEN1 2506/4885KMT2A 4336/4885 |
| US-20230331711-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | VCAM1, ICAM1, HLA-DRB1 | MAPT 2847/4885MEN1 2506/4885KMT2A 4336/4885 |
| US-10906892-B2 | LFA-1 inhibitor and methods of preparation and polymorph thereof | ITGB1, ITGA1, VCAM1 | MAPT 3468/4885MEN1 3219/4885KMT2A 3210/4885 |
| US-20180118726-A1 | LFA-1 INHIBITOR AND METHODS OF PREPARATION AND POLYMORPH THEREOF | ITGB1, ITGA1, VCAM1 | MAPT 3468/4885MEN1 3219/4885KMT2A 3210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.